Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

7.220 +0.220 (+3.14%)

Streaming Delayed Price Updated: 12:20 PM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

30 31 Next >

Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes ↗

October 07, 2024

Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential.

Via Benzinga

Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder ↗

September 26, 2024

New study suggests psilocybin may help treat body dysmorphic disorder by rewiring brain connectivity and reducing obsessive thought patterns.

Via Benzinga

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

September 23, 2024

From Compass Pathfinder Limited

Via Business Wire

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗

September 15, 2024

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Via Talk Markets

MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward? ↗

September 12, 2024

Via Benzinga

Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗

September 10, 2024

While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are...

Via Talk Markets

Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August ↗

September 06, 2024

The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a...

Via Talk Markets

Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down ↗

September 05, 2024

Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy.

Via Benzinga

Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration ↗

September 05, 2024

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.

Via Benzinga

Topics Artificial Intelligence

Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday ↗

August 26, 2024

Via Benzinga

Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week ↗

August 24, 2024

Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past...

Via Talk Markets

Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD ↗

August 15, 2024

This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest...

Via Talk Markets

Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript ↗

August 01, 2024

CMPS earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗

July 31, 2024

Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.

Via Benzinga

Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗

July 14, 2024

The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...

Via Talk Markets

3 Dirt-Cheap Drug Developers With Blockbuster Potential ↗

July 11, 2024

These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.

Via InvestorPlace

3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers ↗

July 08, 2024

These psychedelic drug stocks aren't as radical as once thought as institutional awareness and emphasize on their potential increases.

Via InvestorPlace

3 Psychedelic Stocks to Buy on the Dip: Summer 2024 ↗

July 02, 2024

These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns.

Via InvestorPlace

Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗

June 22, 2024

Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...

Via Talk Markets

Should You Buy the Dip on Compass Pathways Stock? ↗

June 12, 2024

Nothing is going wrong, but one of its peers just hit a serious snag.

Via The Motley Fool

Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know. ↗

June 10, 2024

Regulators were not impressed by one company's petition for approval.

Via The Motley Fool

Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why ↗

June 09, 2024

Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.

Via Talk Markets

Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

June 05, 2024

Via Benzinga

What's Going On With MindMed And Psychedelic Stocks? ↗

June 05, 2024

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD)....

Via Benzinga

DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 05, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 05, 2024

Via Benzinga

Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗

June 05, 2024

Via Benzinga

GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 03, 2024

Via Benzinga

These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring ↗

May 21, 2024

Psychedelic medicines are rapidly gaining legitimacy on several fronts.

Via The Motley Fool

Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon ↗

May 09, 2024

Via Benzinga

Topics Cannabis

< Previous 1 2 3 4 5 6 7 8 9

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Penticton Herald

Penticton Herald

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

All News about COMPASS Pathways Plc - American Depository Shares

Contact us

Sections

Services

Search